MEDICINOVA, INC. Deferred Income Tax Expense (Benefit)
MEDICINOVA, INC. (MNOV) reported Deferred Income Tax Expense (Benefit) of -$1.75 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-02-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2019-02-13
- MEDICINOVA, INC. deferred income tax expense (benefit) for fiscal 2017 was -$1.75M.
- MEDICINOVA, INC. deferred income tax expense (benefit) for fiscal 2014 was $0.00.
- MEDICINOVA, INC. deferred income tax expense (benefit) for fiscal 2013 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2017-12-31 | -$1.75M 10-K · filed 2019-02-13 |
| 2014-12-31 | $0.00 10-K · filed 2015-03-12 |
| 2013-12-31 | $0.00 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |